Human HVEM (Luc) HEK293 Reporter Cell

产品评论
货号-规格
价格
Qty.
CHEK-ATF105-2Vials (1Vial X 2)
询价
Fiber-add-1piece
可选服务
询价
合计0件 产品金额¥ 0

产品信息

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

The Human HVEM (Luc) HEK293 Reporter Cell was engineered to not only express NF-kB signaling response element, but also express the receptor full length human HVEM (Gene ID: 8764). When co-cultured with target cells expressing human BTLA, the BTLA/HVEM interaction drives NF-kB-mediated luminescence. Blocking the BTLA/HVEM interaction by either anti-BTLA or anti-HVEM antibodies results in a decrease in luminescence.

应用说明(Application)

• Screen for anti-human BTLA antibody or anti-human HVEM antibody blocking BTLA/HVEM interaction.

HVEM Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Hygromycin B (20 μg/mL)

培养基(Complete Growth Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

产品数据图

 

Receptor Assay

HVEM FACS

Expression analysis of human HVEM on Human HVEM (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human HVEM (Luc) HEK293 Reporter Cell or negative control cell using
PE-labeled anti-human HVEM antibody

Protocol

 

Application

HVEM APPLICATION

Inhibition of human BTLA overexpressing on CHO cells induced reporter activity by anti-human BTLA antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO/Human BTLA Stable Cell Line. The EC50 of anti-human BTLA neutralizing antibody is approximately 0.212 μg/mL.

Protocol

 

Signaling Bioassay

HVEM SIGNALING

Response to human BTLA (FOLD).
This reporter cell was incubated with CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110) at four different cell densities. The human BTLA overexpressing on CHO cells can activate HVEM signaling with the max induction fold 103.69 at the density of 8x10^4 cells/well.

Protocol

 

Passage Stability

HVEM PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human HVEM (Luc) HEK293 Reporter Cell was incubated with CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110). The human BTLA overexpressing on CHO cells stimulated response demonstrates passage stabilization (fold induction) across passage 7-25.

Protocol

 
 

产品评论
发表评论

背景

Herpesvirus entry mediator (HVEM) is also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFβ (lymphotoxin α) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTβR, the receptor for lymphotoxin αβ heterotrimer. The role of the HVEM LIGHT /LTβ receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.

前沿进展

 
靶点信息
  • 英文全称:

    Tumor necrosis factor receptor superfamily member 14

  • 中文全称:

    肿瘤坏死因子受体超家族成员14

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    0 详情

  • 最高研发阶段:

    临床前

数据表和文档
联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品信息
  • 产品数据图
  • 产品评论
  • 背景